Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A financials
$469.28−0.26%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $838.5M | $823.4M | $977.2M | $860.5M |
| Gross profit | $416.0M | $379.8M | $449.2M | $379.4M |
| Gross margin | 49.6% | 46.1% | 46.0% | 44.1% |
| Operating income | -$65.3M | $10.2M | $76.3M | -$51.8M |
| Net income | -$62.9M | $3.5M | $14.9M | -$62.4M |
| Net margin | −7.5% | 0.4% | 1.5% | −7.3% |
| Diluted EPS | $-0.41 | $0.02 | $0.10 | $-0.41 |
| EBITDA | $127.6M | $68.5M | $134.4M | $100.4M |
| Operating cash flow | -$77.4M | $71.2M | $229.8M | -$33.2M |
| Free cash flow | -$106.2M | $47.0M | $177.8M | -$54.1M |
| Diluted shares | 152.3M | 152.7M | 151.8M | 151.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $184.9M | $133.4M | $298.8M | $293.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.82B | $1.67B | $1.87B | $2.01B |
| Total assets | $6.05B | $6.13B | $6.24B | $6.43B |
| Total liabilities | $3.62B | $3.63B | $3.73B | $3.94B |
| Shareholders' equity | $2.40B | $2.47B | $2.47B | $2.45B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology